Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, Its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients With Relapsed or Refractory Malignancies
UF startup Dialectic Therapeutics, Inc., a Texas-based clinical-stage biotechnology company focused on creating innovative new technologies to treat cancer, announced the dosing of the first patient in a first-in-human, dose-escalation Phase 1 trial evaluating DT2216, the first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology, in patients with relapsed or refractory solid tumor and hematologic malignancies.
Interview with Juan Tomás Hernani, CEO of SATLANTIS
Avión Revue, an international aviation news site, interviewed Hernani about his journey licensing the technology with the University of Florida and upcoming projects.
Oragenics Awarded a $250,000 Grant From the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., announced that it was awarded a small business innovation research grant in the amount of $250,000 (Computer-aided Design for Improved Lantibiotics R41GM136034) for the company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University (FIU).
Cannabix Technologies Ramps Up Beta Testing With THC Breathalyzer and Ships Additional Devices
UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it is ramping up subject beta testing in a high-volume clinic in the Northwestern US and will ship an additional THC Breath Analyzer (THCBA) unit to the site.
AGTC: The New Leader in Ocular Gene Therapy With Sue Washer
Sue Washer, president and CEO of Applied Genetic Technologies Corporation (AGTC), discusses ocular gene therapy with the Eye Care Insider podcast host Joshua Mali, MD.
Local Tech Startup Continues Breakthrough Success in Global Display Industry
UF startup and UF Innovate | The Hub resident Mattrix Technologies has found a way to use technology invented at UF to reduce OLED manufacturing costs for large screens and bring these incredible displays to a wider market.
Revisiting the A-Si Backplane for the Next Generation of AMOLED Displays
Mattrix Technologies has a new approach to AMOLED manufacturing that may soon drive costs down and adoption rates higher in many markets.
Space Startups Launch YEESS To Make Their Case in Europe Presided by SATLANTIS CEO
Six European space startups founded the Young European Enterprises Syndicate (YEESS) presided by SATLANTIS CEO Juan Tomas Hernani.
DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer
UF startup DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, announced the appointment of David Liebowitz, M.D., Ph.D., an industry veteran with over 20 years of experience in oncology drug and viral vaccine development, as chief medical officer.
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of Its SARS-CoV-2 Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.
